{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:55:02Z","timestamp":1771610102571,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1007\/s00277-008-0449-0","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T14:16:38Z","timestamp":1202739398000},"page":"345-352","source":"Crossref","is-referenced-by-count":63,"title":["Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes"],"prefix":"10.1007","volume":"87","author":[{"given":"Aristoteles","family":"Giagounidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Muus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,12]]},"reference":[{"key":"449_CR1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. V.2.2008. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf . Accessed 4 December 2007"},{"key":"449_CR2","volume-title":"The myelodysplastic syndromes: pathobiology and clinical management","author":"TJ Hamblin","year":"2002","unstructured":"Hamblin TJ (2002) Epidemiology of the myelodysplastic syndromes. In: Bennett JM (ed) The myelodysplastic syndromes: pathobiology and clinical management. Marcel Dekker, New York, NY"},{"key":"449_CR3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079\u20132088","journal-title":"Blood"},{"key":"449_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.leukres.2006.10.023","volume":"31","author":"HJ Olney","year":"2007","unstructured":"Olney HJ, Le Beau MM (2007) Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res 31:427\u2013434","journal-title":"Leuk Res"},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2,124 patients. Blood 110:4385\u20134395","journal-title":"Blood"},{"key":"449_CR6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","volume":"251","author":"H Berghe Van den","year":"1974","unstructured":"Van den Berghe H, Cassiman J-J, David G, Fryns J-P, Michaux J-L, Sokal G (1974) Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature 251:437\u2013438","journal-title":"Nature"},{"key":"449_CR7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/beha.2001.0151","volume":"14","author":"HJ Olney","year":"2001","unstructured":"Olney HJ, Le Beau MM (2001) The cytogenetics of myelodysplastic syndromes. Best Prac Res Clin Haematol 14:479\u2013495","journal-title":"Best Prac Res Clin Haematol"},{"key":"449_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","volume":"355","author":"A List","year":"2006","unstructured":"List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al (2006) Lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456\u20131465","journal-title":"N Engl J Med"},{"key":"449_CR9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549\u2013557","journal-title":"N Engl J Med"},{"key":"449_CR10","unstructured":"Celgene Corporation. Revlimid (lenalidomide) 5mg, 10mg, 15mg and 25mg capsules prescribing information USA. Available from: http:\/\/www.revlimid.com\/pdf\/REVLIMID_PI.pdf . Accessed 4 December 2007"},{"key":"449_CR11","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","volume":"47","author":"N Chen","year":"2007","unstructured":"Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466\u20131475","journal-title":"J Clin Pharmacol"},{"key":"449_CR12","doi-asserted-by":"crossref","unstructured":"List AF, Dewald GW, Bennett JM, Giagounidis A, Raza A, Feldman EJ et al (2006) Long-term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome and chromosome deletion 5q. Blood 108:Abstract 251","DOI":"10.1182\/blood.V108.11.251.251"},{"key":"449_CR13","doi-asserted-by":"crossref","unstructured":"Giagounidis AA, Haase S, Platzbecker U, Germing U, Lohrbacher V, Ehninger G et al (2007) Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide. Blood 110:Abstract 1460, 437a","DOI":"10.1182\/blood.V110.11.1460.1460"},{"key":"449_CR14","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Maciejewski JP, Giagounidis A, Wride K, Knight RD, Raza A et al (2007) Lenalidomide-induced cytopenias: relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS). Blood 110:Abstract 821, 252a","DOI":"10.1182\/blood.V110.11.821.821"},{"key":"449_CR15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archinte.162.11.1245","volume":"162","author":"JA Heit","year":"2002","unstructured":"Heit JA, O\u2019Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245\u20131248","journal-title":"Arch Intern Med"},{"key":"449_CR16","first-page":"64","volume":"91","author":"MM Samama","year":"2006","unstructured":"Samama MM, Dahl OE, Mismetti P, Quinlan DJ, Rosencher N, Cornelis M et al (2006) An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica 91:64\u201370","journal-title":"Haematologica"},{"key":"449_CR17","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","volume":"104","author":"AA Khorana","year":"2005","unstructured":"Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:2822\u20132829","journal-title":"Cancer"},{"key":"449_CR18","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063\u20133067","journal-title":"Blood"},{"key":"449_CR19","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/archderm.142.10.1298","volume":"142","author":"HP Sviggum","year":"2006","unstructured":"Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142:1298\u20131302","journal-title":"Arch Dermatol"},{"key":"449_CR20","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-related fatigue. V.4.2007. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/fatigue.pdf . Accessed 4 December 2007"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0449-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T22:17:15Z","timestamp":1588371435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0449-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,12]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0449-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,12]]}}}